First patients in Spain to be treated with Pepaxti

Oncopeptides today announced that the first Spanish hospital will begin treating patients with Pepaxti.

The first order of the drug from a Spanish hospital follows the availability of Pepaxti in the Spanish healthcare system (“Nomenclator”) without restrictions in the reimbursement, enabling hematologists to incorporate this new therapeutic option to the current pipeline for relapsed, refractory multiple myeloma management.

“The reception of this innovation in the medical community is a testament to the unmet medical need that this drug fills,” says Sofia Heigis, CEO of Oncopeptides. “We look forward to more patients and professionals both in Spain and the rest of Europe benefitting from the clinical and quality of life results demonstrated by this treatment.”

In total, 16 Spanish hospitals and more than 100 patients have participated in the clinical trials that have led to the approval of the first drug in the peptide conjugate class for the treatment of relapsed, refractory multiple myeloma.

Questions and answers for investors

What is this?

Oncopeptides has received its first order for Pepaxti from a Spanish hospital.

Does this change your communicated timeline, where you expect sales to take off after the summer?

No. That said, we already see a strong unmet medical need and are happy to be able to address it as needed.

How are doctors able to order Pepaxti before regional access has been granted?

Before the drug has been entered in the regional healthcare registries, doctors can in some cases order the drug centrally.

How many vials have you sold?

For competitive reasons, Oncopeptides do not disclose individual sales on a national level at this point.